New eczema ointment shows promise in early trial

NCT ID NCT07355075

Recruiting now Symptom relief Sponsor: Turn Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 study tests an experimental ointment called GX-03 in adults with moderate-to-severe eczema. About 110 to 200 participants will apply either the active ointment or a placebo for 8 weeks. Researchers will measure improvements in skin rash, itch, and patient-reported symptoms to see if GX-03 works better than the placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GX-03 topical ointment
What this could lead to: If it works, this could offer a new topical treatment option for people with moderate-to-severe eczema, helping to clear skin and reduce itch.
What could go wrong: This is an early Phase 2 trial with only 110-200 participants. The ointment is compared to a placebo (vehicle), so it may not prove more effective. Results are still uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema Eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS ECZEMA ECZEMA ATOPIC DERMATITIS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

ALS Global
RECRUITING

Irving, Texas, 75062, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.